Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAB001 Dose-Escalation Study in Healthy Subjects
NCT07545018Phase 1Completed
- Sponsor
- Zhongshan Laibo Ruichen Biopharmaceutical
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LLP2A-alendronate in osteonecrosis of the femoral head (ONFH) (3 arms), sponsored by Zhongshan Laibo Ruichen Biopharmaceutical. Primary endpoints: Adverse Events and Serious Adverse Events. Started Feb 2023; status: completed.
02
Drugs
LLP2A-alendronate
03
Conditions
osteonecrosis of the femoral head (ONFH)
Beyond the preview
Go deeper on NCT07545018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545018.